CJC-1295 (no DAC)
5MGModified GRF (1-29) secretagogue analog.
6 peer-reviewed citations for this compound
Read the sourcesVolume tiers count vials of this compound at this strength. Mixing different compounds does not combine toward a tier.
- ≥99% purity specification
- Secure checkout
- Ships in 1 business day
- Research use only
Released against a ≥99% HPLC purity specification and supplied as a sealed laboratory reagent for in vitro research use only.
- Type
- Modified GRF (1-29) — growth-hormone-releasing peptide analog
- CAS number
- 863288-34-0
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3367.9 g/mol
- Amino acids
- 29
- Form
- Lyophilized powder
- Vial strength
- 5MG
- Purity specification
- ≥99% by HPLC
Identifiers are published properties of the molecule. Values we cannot confirm are omitted rather than estimated.
Dispatch
Ships within 1 business day of order confirmation, from the US. Vials ship lyophilized at ambient temperature; move them to the storage condition below on arrival.
Lyophilized
Store at -20°C, protected from light. Stable 24+ months sealed.
Reconstituted
Store at 2-8°C. Use within approximately 30 days.
How CJC-1295 (no DAC) is described to act.
CJC-1295 is a tetrasubstituted analog of human growth hormone-releasing factor hGRF(1-29) that acts as an agonist at the GRF (GHRH) receptor on anterior pituitary somatotrophs; the substitutions confer enhanced in vitro stability against dipeptidyl peptidase-IV. The form characterized in the peer-reviewed literature additionally carries an N-epsilon-3-maleimidopropionamide lysine at the C-terminus, which bioconjugates in vivo to the free thiol on Cys34 of serum albumin and extends plasma residence; material sold without this drug-affinity-complex moiety corresponds to the modified GRF(1-29) backbone alone, for which no separate pharmacology literature was identified. Systematic alanine- and Aib-scanning structure-activity studies of hGHRH(1-29)-NH2 map which residue substitutions raise or abolish in vitro GH-releasing potency. Readers should note that the animal and human data below were generated with the albumin-binding conjugate, not the non-DAC peptide.
Mechanistic descriptions summarize published in vitro and animal work. They are not a representation of efficacy or safety in any subject, and no administration guidance is given or implied.
In normal male Sprague Dawley rats, subcutaneous administration produced acute plasma GH secretion with roughly a fourfold greater GH area under the curve over 2 h than unmodified hGRF(1-29), and Western blotting detected a CJC-1295 immunoreactive species on the serum albumin band within 15 minutes and beyond 24 hours, with the compound present in plasma past 72 hours. In GHRH-knockout mice, five weeks of daily dosing normalized body weight and length, increased total pituitary RNA and GH mRNA, and immunohistochemistry indicated somatotroph proliferation. Two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21-61 examined peak concentrations and area under the curve of GH and IGF-I plus standard pharmacokinetic parameters, reporting an estimated half-life of 5.8-8.1 days. A separate human study assessed overnight GH pulsatility by 20-minute sampling and reported that pulse frequency and magnitude were unaltered while trough GH levels rose. A proteomic study in 11 healthy young men used two-dimensional gel electrophoresis and mass spectrometry to examine serum protein profile changes one week after injection.
Sources & references
Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject. All research findings presented are sourced from peer-reviewed journals and are provided for educational reference only.
- 01Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Sackmann-Sala L, et al. · Growth Horm IGF Res, 2009
- 02Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, et al. · J Clin Endocrinol Metab, 2006
- 03Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M, et al. · Am J Physiol Endocrinol Metab, 2006
- 04Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, et al. · J Clin Endocrinol Metab, 2006
- 05
- 06Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies
Cervini LA, et al. · J Med Chem, 1998
Every entry links to its record at the publisher or on PubMed. Titles are reproduced exactly as published.
Further searches
Live database searches for CJC-1295 (no DAC), run against the current index and retrieved independently of this site.
Bench handling, not a dosing guide.
Intended use
Supplied exclusively as a research reagent for in vitro and laboratory use by qualified researchers. Not a drug, dietary supplement, cosmetic or medical device, and not for human or veterinary use. No dosing, route or administration guidance is provided for any compound in this catalog.
Personal protection
Handle in a controlled laboratory environment with gloves and eye protection. Avoid generating or inhaling airborne particulate when opening a vial, and do not handle the material outside a designated work area.
Opening and reconstitution
Lyophilized peptides are hygroscopic. Let the sealed vial equilibrate to room temperature before opening so atmospheric moisture does not condense onto the powder. Reconstitute by directing diluent down the vial wall and swirling until dissolved — do not shake, which shears and foams the peptide.
Stability and aliquoting
Store at -20°C, protected from light. Stable 24+ months sealed. Store at 2-8°C. Use within approximately 30 days. Aliquot reconstituted material and minimize repeated freeze-thaw cycles.
Waste disposal
Dispose of unused material, reconstituted solutions and sharps through your institution's chemical and biological waste stream, in accordance with local regulations. Do not dispose of research material in domestic waste or to drain.
Others in secretagogue research
CJC (no DAC) / Ipamorelin
Mod GRF (1-29) and ipamorelin blend.
IGF-1 LR3
83-residue recombinant IGF-1 analog.
Ipamorelin
Selective pentapeptide growth-hormone secretagogue.
Sermorelin
GHRH (1-29) amide, 29 residues.
Important research notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
This material is supplied exclusively as a research reagent for in vitro and laboratory use by qualified researchers. It is not a drug, dietary supplement, cosmetic, or medical device, is not intended for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any disease. No dosing, administration, therapeutic, or benefit claims are made or implied. Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.